Brinker Harding's Pharma Investments Contradict Drug Price Campaign Pledge
Concerns Arise Over Brinker Harding's Pharmaceutical Investments as He Campaigns for Congress
As Brinker Harding, a Republican city councilor from Omaha, vies for a congressional seat in Nebraska’s 2nd District, his stance on drug pricing is drawing scrutiny. Harding, who is facing off against Democrat Denise Powell, has pledged to address the rising costs associated with pharmaceuticals.
In a recent social media video, Harding outlined his commitment to affordable healthcare, advocating for a most-favored nation policy that aims to align Medicaid drug payments with those of other nations. This policy, first proposed by former President Donald Trump, seeks to lower drug prices significantly and is seen as a potential savings measure for the federal government. However, detractors question whether this approach will substantially reduce the pharmaceutical industry’s impact on drug pricing or actually lead to lower costs for patients.
Harding reiterated his support for this issue in an op-ed published earlier this year in the Omaha World-Herald, where he criticized the practice of using taxpayer funds to support large pharmaceutical companies and insurers during financial difficulties.
Despite his public commitments, financial statements reveal that Harding and his spouse hold investments between $100,000 and $125,000 in prominent pharmaceutical companies Pfizer and AbbVie, both of which have faced legal challenges related to price hikes and alleged profiteering. Recent allegations against Pfizer include a settlement over antitrust claims related to the price of EpiPens, while AbbVie has been scrutinized for the high costs of its product Humira.
Furthermore, the two companies had previously engaged in a voluntary most-favored nation pricing agreement under the Trump administration, yet they have since increased their drug prices in 2026, raising further questions about their commitment to affordability.
The topic of healthcare affordability is particularly salient in the current election cycle, with Powell's campaign advocating for a monthly cap of $35 on insulin costs for all Americans. This proposal highlights the ongoing debate regarding access to necessary medications and the strategies needed to achieve lower drug prices.